Skip to main content
Equibles
CRON logo

CRON · Cronos Group Inc. · Metrics

Track CRON — free

Use CRON with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CRON.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$3.35 -0.04 (-1.04%) Q2 2026 earnings call transcript
Rebalance outlook locked
Market Cap
$1.25B
Shares
368.41M
Volume · Oct 28 307.91K Avg daily vol (3M) 1.13M

CRON metrics

100 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$3.38
Market cap
$1.25B

Price action

20 metrics
Price change (1W)
+3.0%
Price change (30D)
-0.9%
Price change (3M)
+18.6%
Price change (6M)
+27.5%
Price change (YTD)
+28.5%
Price change (1Y)
+36.8%
Trailing year
Price change (5Y)
-36.1%
52-week high
$3.55
52-week low
$2.30
Change from 52-week high
-4.8%
Change from 52-week low
+47.0%
Annualized volatility
39.8%
Annualized volatility (3M)
39.0%
Beta
0.6
RSI (14D)
57.4
Price vs SMA 50
+2.5%
Price vs SMA 200
+18.9%
Avg volume (3M)
1.13M
Relative volume
0.7
Average dollar volume
$3.65M

Company

3 metrics
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Shares outstanding
368.41M

Valuation

12 metrics
P / E (TTM)
17.8
Trailing earnings · reciprocal yield 5.6%
PEG ratio
—
EV / revenue
2.5×
reciprocal yield 40.0%
EV / EBITDA
36.7×
reciprocal yield 2.7%
EV / EBIT
—
P / sales
7.0×
reciprocal yield 14.4%
P / book
1.2
reciprocal yield 85.8%
FCF yield
4.0%
TTM · current market cap
Buyback yield
3.1%
P / FCF
25.0
reciprocal yield 4.0%
P / operating cash flow
20.7
reciprocal yield 4.8%
Earnings yield
5.5%

Historical valuation

8 metrics
P / E historical average (3Y)
21.8×
reciprocal yield 4.6%
P / E historical average (5Y)
21.8×
reciprocal yield 4.6%
EV / revenue historical average (3Y)
0.3×
reciprocal yield 377.9%
EV / revenue historical average (5Y)
0.3×
reciprocal yield 377.9%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
3.1%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
2026-11-05
Last earnings
2026-08-06

Profitability

9 metrics
Gross margin
45.9%
Operating margin
-1.4%
Trailing 12 months
Net margin
38.2%
Gross profit (TTM)
$82.12M
Operating profit (TTM)
−$2.43M
Net income (TTM)
$68.38M
Trailing 12 months
Diluted EPS (TTM)
$0.19
FCF margin
27.8%
Effective tax rate
-15.7%

Per share

11 metrics
Revenue per diluted share (TTM)
$0.47
Gross profit per diluted share (TTM)
$0.22
Operating profit per diluted share (TTM)
$-0.01
EBITDA per diluted share (TTM)
$0.03
Net income per diluted share (TTM)
$0.18
Operating cash flow per diluted share (TTM)
$0.16
Free cash flow per diluted share (TTM)
$0.13
Capital expenditures per diluted share (TTM)
$0.03
R&D per diluted share (TTM)
$0.01
Stock compensation per diluted share (TTM)
$0.02
Book value per share
$2.87

Growth

11 metrics
Revenue growth YoY
+58.4%
Year over year
Net income growth YoY
-123.0%
Revenue (TTM)
$179.09M
Trailing 12 months
EPS growth YoY
-118.2%
Shares change YoY
-2.7%
Year over year · fewer shares
Revenue CAGR (3Y)
+19.1%
Revenue CAGR (5Y)
+25.7%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
6.4%
Return on assets
5.8%
Debt / equity
0.0
Current ratio
16.2
EBITDA (TTM)
$12.20M
Free cash flow (TTM)
$49.82M
Quick ratio
15.2
Interest coverage
—
Net debt / EBITDA
-65.3
Return on invested capital
—
Trailing 12 months
Net cash
$797.02M
Latest balance sheet
Cash & equivalents
$467.02M
Total assets
$1.18B
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$60.05M
Capital expenditures (TTM)
$10.24M
R&D (TTM)
$5.36M
SG&A (TTM)
—
Stock compensation (TTM)
$6.45M
R&D / revenue
3.0%
Stock compensation / revenue
3.6%

Ownership (13F)

9 metrics
13F filers
195
13F filer change QoQ
+2
Institutional ownership
13.3%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
7.2%
Private-fund adviser ownership
4.0%
Active holders' share change QoQ
-2.9%
Holder tenure
16.9
Price vs estimated holder cost
+17.5%

Ownership (registered funds)

1 metrics
Index-fund ownership
1.4%

Short interest

3 metrics
Short interest
1.1%
Latest settlement · 4.8 days to cover
Days to cover
4.8d
Short-squeeze score
54 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1656472 CUSIP 22717L101 13F (30d) 34 filings 34 filers Visit website Investor relations